
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.
That’s exactly what happened when J.P. Morgan recently upgraded Gilead Sciences Inc. (NASDAQ: GILD), highlighting renewed confidence in the healthcare space.